antibiot
import
exampl
man
learn
natur
improv
live
condit
first
observ
microb
abl
produc
substanc
capabl
kill
pathogen
came
italian
scientist
vincenzio
tiberio
show
antibacteri
activ
natur
substanc
produc
mold
ernest
duchesn
franc
publish
doctor
thesi
present
mold
penicillium
glaucum
possess
antibacteri
properti
alexand
flame
succeed
definit
identifi
world
first
antibiot
substanc
isol
mold
penicillium
notatum
defin
benzylpenicillin
penicillin
g
first
industri
product
came
howev
howard
florey
ernst
bori
chain
continu
work
flame
oxford
thu
pearl
harbor
attack
mass
product
could
initi
enough
penicillin
produc
treat
wound
soldier
alli
forc
nobel
prize
physiolog
medicin
assign
flame
florey
chain
era
antibiot
begun
sever
molecul
produc
microb
follow
penicillin
antibiot
mankind
could
claim
histor
success
etern
war
pathogen
howev
soon
clear
antibiot
definit
weapon
book
publish
stanley
falkow
wrote
owe
chemotherapi
antibiot
debt
reduc
high
mortal
iti
rate
mani
bacteri
infect
hygien
vaccin
debt
prevent
howev
help
solv
problem
infecti
diseas
chemotherapi
creat
problem
problem
creat
antibiot
gener
bacteri
strain
resist
multipl
antibiot
event
report
first
time
isol
japan
strain
shigella
flexneri
resist
streptomycin
tetracyclin
chloramphenicol
sulfonamid
today
antimicrobi
resist
amr
grown
proport
mani
pathogen
bacteria
resist
multipl
antibiot
includ
neisseria
gonorrhoea
staphylococcu
aureu
pseudomona
aeruginosa
salmonella
typhi
shigella
escherichia
coli
acinetobact
proteu
klebsiella
serratia
strep
tococcu
pneumonia
mycobacterium
tuberculosi
vibrio
cholera
helicobact
pylori
other
case
bacteria
becam
resist
avail
antibiot
verg
becom
untreat
consequ
amr
perhap
alarm
emerg
problem
infecti
diseas
global
amr
alreadi
caus
deathsyear
forecast
caus
million
deathsyear
higher
million
death
caus
cancer
today
exampl
look
pneumonia
also
known
pneumococcu
human
pathogen
major
caus
communityacquir
pneumonia
bacteri
mening
bacteremia
otiti
media
past
strain
pneumonia
sensit
penicillin
wherea
today
penicillin
resist
goe
variou
part
world
thu
time
old
antibiot
becom
less
effect
lose
efficaci
make
search
new
molecul
differ
mechan
action
prioriti
alarm
document
call
action
ask
new
antibiot
issu
govern
uk
usa
european
union
eu
intern
organ
world
health
organ
unit
nation
gener
assembl
world
bank
interest
fight
increas
amr
intensifi
new
incent
research
develop
new
drug
deploy
million
us
alloc
new
exist
initi
aim
acceler
develop
ment
new
antibiot
exampl
innov
medicin
initi
biggest
publicpriv
program
biomed
scienc
eu
commiss
fund
sever
project
defin
new
drug
bad
bug
initi
includ
carbx
collabor
us
uk
partner
global
antibiot
research
develop
partnership
collabor
drug
neglect
diseas
initi
also
interest
german
propos
global
union
antibiot
research
develop
guard
aim
fund
coordin
facil
antibiot
research
develop
februari
publish
document
partial
report
hereaft
first
ever
list
antibioticresist
prioriti
pathogen
catalog
document
strongli
underlin
need
new
treatment
thu
search
new
antimicrobi
drug
must
remain
great
prioriti
howev
import
realiz
pipelin
new
antibiot
promis
therebi
make
unlik
problem
solv
along
line
hand
anoth
tool
togeth
antibiot
contribut
conquer
elimin
mani
infecti
diseas
ie
vaccin
promis
pipelin
thank
new
technolog
thu
vaccin
possibl
make
big
contribut
control
amr
analysi
vaccin
antibiot
contribut
conquer
infecti
diseas
last
centuri
origin
publish
group
one
author
paper
recent
reanalyz
depth
kennedi
read
figur
analysi
show
resist
antibiot
inevit
emerg
everi
time
new
antibiot
introduc
start
process
select
target
bacteria
eventu
make
antibiot
useless
consequ
continu
need
fresh
suppli
novel
antibiot
maintain
effect
therapeut
treatment
strategi
work
well
identif
new
antibiot
abund
howev
sinc
pipelin
new
antibiot
dri
abl
discov
new
class
antibiot
mark
contrast
kennedi
read
show
use
vaccin
long
time
gener
littl
resist
thu
vaccin
control
infect
long
period
time
without
becom
obsolet
occur
vaccin
work
prophylact
prevent
start
infect
drug
work
therapeut
ongo
infect
bacteria
prolifer
mutat
allow
drug
select
resist
variant
furthermor
drug
target
metabol
pathway
pathogen
wherea
vaccin
induc
protect
immun
respons
multipl
antigen
target
conclud
select
fewer
opportun
act
upon
vaccin
antibiot
treatment
still
vaccin
antibiot
import
control
infect
tabl
report
major
differ
mode
action
vaccin
antibiot
provid
inform
guid
us
take
advantag
strength
minim
weak
comparison
evid
antibiot
lifesav
tool
figur
time
detect
resist
human
pathogen
antimicrobi
red
vaccin
green
black
x
symbol
indic
insurg
resist
line
start
product
introduct
yellow
star
except
smallpox
vaccin
began
much
earlier
modif
ref
permiss
publish
use
acut
bacteri
infect
although
often
improp
excess
use
caus
bacteri
resist
continu
increas
fashion
avail
vaccin
control
infect
may
allow
us
decreas
use
antibiot
gener
less
amr
permit
effici
use
exist
new
antibiot
acut
infect
shown
figur
howev
case
resist
evolv
vaccin
due
sever
caus
fact
vaccin
protect
diseas
may
capabl
complet
prevent
pathogen
colon
transmiss
case
acellular
pertussi
vaccin
caus
serotyp
replac
vaccin
vaccin
includ
serotyp
case
vaccin
pneumonia
thu
even
vaccin
search
better
protect
antigen
ag
import
particularli
antibioticresist
infect
may
group
expert
coordin
economist
jim
oneil
publish
comprehens
report
entitl
tackl
drugresist
infect
global
among
mani
indic
prevent
increas
global
problem
amr
entir
section
devot
vaccin
hereaft
report
part
section
must
reduc
demand
antimicrobi
similarli
document
prioriti
pathogen
stress
role
vaccin
global
amr
crisi
remain
great
import
sinc
year
anniversari
foundat
serolog
vaccinolog
institut
achil
sclavo
forum
discuss
import
issu
vaccin
world
take
place
everi
year
siena
itali
annual
meet
aim
analyz
stateoftheart
import
theme
field
vaccin
expand
vision
year
come
particip
excel
speaker
expert
discuss
ensur
high
qualiti
meet
whose
conclus
publish
intern
journal
meet
organ
close
popular
event
hors
race
name
palio
di
siena
town
worldwid
famou
thu
meet
call
palio
meet
recent
acquisit
vaccin
compani
siena
gsk
venu
meet
move
locat
usa
europ
tradit
name
maintain
topic
meet
vari
mission
alway
base
one
follow
pillar
must
defin
stateoftheart
cut
edg
topic
relat
infecti
diseas
must
advoc
scienc
polici
promot
progress
improv
human
health
must
strateg
forum
aim
build
new
initi
tabl
report
topic
palio
meet
year
therefor
almost
mandatori
subject
palio
meet
grow
emerg
caus
antibiot
failur
titl
priorit
vaccin
fight
antimicrobi
resist
event
shortli
follow
meet
organ
david
salisburi
march
chatham
hous
london
london
meet
provid
clear
consensu
vaccin
complement
action
antibiot
contribut
control
reduc
sometim
elimin
diseas
caus
amr
pathogen
intervent
thu
main
scope
palio
meet
build
conclus
london
meet
pose
question
make
vaccin
achiev
full
potenti
becom
one
top
tool
tackl
amr
inde
discuss
led
conclud
need
make
stronger
evidencebas
case
support
import
vaccin
amr
prevent
one
exampl
repres
vaccin
main
strain
pneumonia
vaccin
reduc
pneumonia
case
first
decad
centuri
parallel
decreas
number
infect
resist
frontlin
antibiot
introduct
south
africa
pneumococc
vaccin
achiev
analog
result
furthermor
interest
note
high
use
antibiot
prescrib
treat
opportunist
bacteri
infect
peopl
weaken
flu
prevent
flu
vaccin
employ
figur
interplay
b
cell
technolog
structur
biolog
vaccin
design
shown
revers
vaccinolog
approach
flow
path
represent
analysi
human
b
cell
repertoir
lead
identif
protect
ab
vaccin
infect
subject
upper
left
singl
b
cell
sort
cultur
enabl
direct
screen
select
natur
produc
ab
desir
function
recoveri
correspond
ig
gene
sequenc
approach
allow
us
interrog
singlesort
b
cell
direct
screen
ab
function
recov
ig
sequenc
produc
ab
interest
recombin
protein
finetun
properti
structur
character
recombin
monoclon
ab
bound
target
antigen
ag
lead
detail
definit
protect
epitop
right
inset
show
cocryst
structur
agab
fab
complex
identifi
protect
epitop
red
engin
protect
epitop
lead
design
novel
optim
immunogen
exampl
mount
epitop
orient
multicopi
array
nanoparticl
act
carrier
increas
epitopefocus
immun
respons
structurebas
ag
design
new
ag
develop
best
formul
deliveri
system
test
human
ref
permiss
publish
need
make
public
data
gener
vaccin
compani
vaccin
effect
amr
continu
monitor
circul
resist
bacteri
strain
discuss
continu
idea
action
becom
better
defin
global
strateg
effort
develop
portfolio
vaccin
target
amr
becom
mandatori
vaccin
becom
advantag
weapon
curb
amr
effect
prevent
infect
huge
improv
consequ
enorm
technolog
develop
last
two
decad
sinc
introduct
jenner
vaccin
smallpox
field
vaccin
steadili
progress
last
year
vaccin
develop
enorm
benefit
omic
approach
thu
new
potenti
vaccin
candid
discov
much
shorter
time
past
vaccin
develop
empir
new
techniqu
genom
sequenc
introduc
late
complet
chang
process
discov
novel
vaccin
ag
revers
vaccinolog
approach
show
start
sequenc
inform
possibl
discov
protect
ag
without
handl
microb
recent
licens
vaccin
meningococcu
b
first
vaccin
produc
revers
vaccinolog
last
decad
vaccin
design
potenti
new
technolog
lead
approach
name
revers
vaccinolog
summar
figur
approach
take
advantag
human
immunolog
design
optim
vaccin
ag
thank
better
knowledg
handl
human
b
cell
select
favor
donor
possibl
produc
highli
specif
recombin
monoclon
antibodi
mab
also
agbind
fragment
fab
analysi
structur
biolog
approach
bring
studi
target
ag
complex
fab
also
possibl
discov
protect
epitop
capabl
induc
broadli
neutral
ab
furthermor
new
comput
approach
allow
obtain
complet
novel
immunogen
capabl
induc
protect
viral
infect
new
structurebas
power
vaccin
molecul
alreadi
design
screen
human
mab
convalesc
peopl
obtain
molecular
structur
ag
agab
complex
describ
earlier
exampl
identif
pentam
key
ag
cytomegaloviru
cmv
prefus
ag
respiratori
syncyti
viru
rsv
recent
promis
cmv
vaccin
candid
recombin
form
fusion
protein
gb
howev
human
trial
gb
combin
potent
adjuv
show
moder
efficaci
therefor
vaccin
develop
put
hold
later
isol
human
mab
peopl
previous
expos
cmv
demonstr
potent
cmv
neutral
antibodi
recogn
gb
complex
ag
made
five
protein
pentam
recombin
form
pentam
induc
neutral
antibodi
order
magnitud
potent
induc
gb
new
ag
promis
candid
cmv
vaccin
soon
undergo
human
trial
case
rsv
possibl
obtain
human
mab
palivizumab
bind
epitop
present
f
protein
prefus
pref
postfus
postf
conform
initi
studi
develop
rsv
vaccin
mainli
focus
use
postf
protein
unlik
pref
highli
stabl
solubl
ag
display
onto
viruslik
particl
howev
experiment
vaccin
base
whole
viru
live
attenu
viru
postf
protein
fail
yield
appropri
level
safeti
efficaci
scenario
chang
isol
character
human
neutral
mab
elicit
natur
infect
show
major
antibodi
specif
pref
form
protein
fail
crossreact
postf
conform
structurebas
design
stabil
rsv
pref
protein
eventu
obtain
complement
crystal
structur
pref
protein
complex
highli
neutral
antibodi
neutral
studi
design
pref
protein
could
induc
neutral
antibodi
time
potent
elicit
previou
vaccin
present
test
human
trial
conclud
interrog
human
antibodi
respons
allow
us
identifi
pathogen
epitop
like
protect
difficult
discov
convent
technolog
far
isol
human
mab
success
use
identifi
viral
ag
could
discov
convent
technolog
hand
data
yet
regard
identif
new
ag
antibacteri
vaccin
proofofconcept
obtain
viral
ag
would
import
appli
approach
identif
novel
bacteri
ag
allow
us
design
innov
vaccin
antibioticresist
pathogen
therebi
effect
tackl
press
global
health
emerg
time
consid
find
effect
solut
fight
antibiot
resist
win
battl
neverend
war
pathogen
microorgan
discuss
human
speci
experienc
impress
prolong
life
expect
improv
life
condit
due
hygien
antibiot
vaccin
one
pillar
weaken
point
affect
import
medic
methodolog
first
import
surgeri
also
immunosuppress
chemotherapi
consequ
organ
transplant
great
success
medicin
era
infecti
diseas
could
sever
reduc
life
span
abl
surviv
import
medic
treatment
even
accident
wound
possibl
solut
sight
develop
combin
preventivetherapeut
approach
vaccin
one
two
arm
chemotherapi
one
reason
believ
combin
two
approach
result
overal
success
main
reason
differ
mode
action
vaccin
antibiot
first
vaccin
rare
capabl
gener
resist
anoth
critic
differ
antibiot
vaccin
rate
discoveri
new
effect
molecul
past
new
antibiot
identifi
regularli
reach
clinic
particularli
three
decad
sinc
howev
new
molecul
introduc
clinic
use
opposit
situat
occur
case
vaccin
develop
increas
speed
today
new
vaccin
becam
avail
sinc
consequ
introduct
new
technolog
recombin
dna
led
gener
new
synthet
sequenc
therefor
obtain
great
reduct
incid
bacteri
mening
caus
haemophilu
influenza
pneumonia
neisseria
meningitidi
thank
new
gener
effect
conjug
vaccin
gener
chemic
technolog
coval
link
bacteri
polysaccharid
protein
recent
genom
sequenc
open
access
higher
level
vaccin
design
sinc
made
possibl
predict
thousand
protein
encod
bacteri
gene
identifi
like
expos
cell
surfac
search
new
vaccin
candid
approach
defin
revers
vaccinolog
result
first
import
protein
vaccin
meningococcu
b
use
worldwid
final
better
understand
mechan
regul
induct
protect
immun
respons
open
possibl
introduc
vaccin
formul
new
moieti
make
effect
substanc
defin
gener
name
adjuv
differ
mechan
action
vaccin
antibiot
enorm
antibiot
famili
molecul
pro
duce
microorgan
kill
microorgan
make
effect
capabl
reach
poison
target
across
strong
barrier
bacteri
cell
wall
avoid
eject
potent
efflux
pump
biochem
modif
target
microorgan
make
antibiot
ineffici
among
billion
bacteria
present
infect
modif
stochast
aris
frequent
vaccin
molecul
capac
evok
host
protect
activ
infect
interact
immun
system
host
system
evolut
develop
sophist
mechan
recogn
destroy
kind
danger
agent
essenti
distinguish
molecul
differ
self
human
immun
system
potenti
recogn
ag
univers
even
never
encount
thank
complex
gene
rearrang
mechan
thu
quit
obviou
potenti
vaccin
protect
us
extraordinari
learn
immun
system
better
design
strategi
develop
tool
protect
health
infect
instanc
case
possibl
cure
establish
infect
administ
patient
specif
antibodi
produc
lab
new
technolog
way
antiinfect
antibodi
could
consid
new
kind
antibiot
famili
even
though
much
expens
time
strategi
comb
antibiot
vaccin
remain
sustain
option
allow
us
avoid
afford
way
amr
threat
wish
stress
seriou
threat
expect
amr
caus
million
deathsyear
embark
complex
combin
studi
import
investig
role
exist
vaccin
could
resist
infect
inde
indic
unconvent
use
exist
vaccin
could
provid
import
advantag
instanc
new
zealand
new
vaccin
mening
b
introduc
year
mening
b
outbreak
end
vaccin
still
produc
tradit
techniqu
compos
bacteri
outer
membran
vesicl
recent
studi
popul
vaccin
vaccin
reveal
protect
gonorrhea
sexual
transmit
infect
induc
n
gonorrhoea
becom
resist
antibiot
reason
protect
like
due
fact
bacteria
caus
mening
gonorrhea
genet
relat
furthermor
current
evid
show
exist
pneumococc
vaccin
reduc
amr
due
fact
prevent
infect
therebi
reduc
carriag
transmiss
antibioticresist
bacteria
anoth
exampl
influenza
vaccin
indirectli
reduc
incid
fever
sick
therebi
minim
use
often
misus
antibiot
increas
amr
one
sever
alarm
signal
profound
effect
human
activ
world
life
tri
solv
problem
infect
resist
antibiot
critic
point
difficulti
obtain
new
antibiot
alreadi
discuss
classic
approach
work
anymor
thu
need
devis
complet
novel
approach
passiv
immun
ie
administr
immun
antibodi
could
perhap
solut
solv
issu
sustain
nowaday
immun
antibodi
produc
low
amount
high
cost
begin
last
centuri
immun
antibodi
abl
neutral
bacteri
toxin
produc
big
anim
larg
employ
contribut
build
industri
sector
serum
institut
evolv
today
vaccin
industri
hope
new
technolog
allow
us
reviv
serolog
concept
make
new
tool
infect
revolutionari
approach
would
make
bacteria
live
within
us
microbiota
becom
alli
fight
infect
alreadi
mention
larg
compon
bodi
bacteria
increas
number
studi
indic
gut
microbiota
influenc
health
patholog
condit
intestin
microb
influenc
host
energi
metabol
intestin
epitheli
prolifer
immun
respons
shown
microbiota
composit
could
influenc
vaginosi
obes
inflammatori
bowel
diseas
function
bowel
disord
allergi
diseas
increas
number
studi
suggest
educ
microbiota
combat
metabol
chronic
diseas
could
also
case
fight
infect
sever
candid
vaccin
develop
pipelin
sinc
last
year
sure
emerg
face
chang
health
prioriti
vaccin
antibioticresist
bacteri
strain
move
top
wrote
manuscript
rr
critic
revis
